Add time:07/30/2019         Source:sciencedirect.com

AimPrevious clinical studies have demonstrated that tangganjian (TGJ), a modern Chinese prescribed medicine, has a clinical effect in the treatment of type 2 diabetes mellitus (T2DM) with nonalcoholic fatty liver disease (NAFLD). Our study aimed to investigate whether the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway is involved in this therapeutic effect.

We also recommend Trading Suppliers and Manufacturers of IRS 19 (cas 112444-82-3). Pls Click Website Link as below: cas 112444-82-3 suppliers